Abstracts tagged "Tofacitinib"

Abstract Number: 016 • 2023 Pediatric Rheumatology Symposium
Gene Expression Changes in Polyarticular Juvenile Idiopathic Arthritis Following Tofacitinib Treatment
Esraa Eloseily¹, Alex Pickering², Sanjeev Dhakal³, Alexei Grom³, Hermine Brunner³ and Sherry Thornton⁴, ¹Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnti, OH, ²Department of Biomedical Informatics, Harvard Medical School, Boston, MA, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Despite advances in the understanding of juvenile idiopathic arthritis (JIA) pathophysiology, personalized treatments informed by gene transcriptomic profiles remain elusive. We aimed toexamine the…
Abstract Number: 1704 • ACR Convergence 2021
Tofacitinib in Rheumatoid Arthritis: Is There a Correlation Between a Rapid Analgesic Effect and a Decrease in Activity After 3 and 6 Months?
Elena Pogozheva¹, Andrey Karateev¹, Evgeniy Nasonov¹, Alexander Lila¹, Vadim Mazurov², Rusanna Samigullina³, Diana Chakieva⁴, Anna Dadalova⁴, Anna Dyo⁴, Andrey Baranov⁵, Natalia Lapkina⁵, Ekaterina Kol’tsova⁶, Ivan Shchendrigin⁷, Tatyana Rasevich⁸, Antonina Davydova⁹, Irina Shafieva¹⁰, Inna Bashkova¹¹, Daria Bobrikova¹², Irina Kushnir¹³, Elena Kalinina¹⁴, Tatiana Sal’nikova¹⁵, Valentina Sorotskaya¹⁶, Irina Marusenko¹⁷, Olga Semagina¹⁸, Irina Vinogradova¹⁹, Diana Krechikova²⁰, Natalia Kiryukhina²¹, Irina Semizarova²², Dzhamilya Murtazalieva²³ and Marina Semchenkova²⁴, ¹V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia, ²Mechnikov North-Western State Medical University, Saint Petersburg, Russia, ³Mechnikov North-Western State Medical University, St.Petersburg, Russia, ⁴Mechnikov North-Western State Medical University, St. Petersburg, Russia, ⁵Yaroslavl State Medical University, Yaroslavl, Russia, ⁶Scientific and Research Institute of Health Care Organization, Moscow, Russia, ⁷Stavropol Regional Clinical Hospital, Stavropol, Russia, ⁸Astrakhan Region Alexandro-Mariinsky Regional Clinical Hospital, Astrakhan, Russia, ⁹Regional Clinical Hospital №1 named. prof. S. V. Ochapovskogo, Krasnodar, Russia, ¹⁰Samara State Medical University of the Ministry of Health of the Russian Federation, Samara, Russia, ¹¹Advisory Polyclinic Chuvash State University named after I. N. Ulyanov, Cheboksary, Russia, ¹²Regional Clinical Hospital No. 1, Tyumen', Russia, ¹³Kemerovo regional clinical hospital, Kemerovo, Russia, ¹⁴Volgograd State Medical University, Volgograd, Russia, ¹⁵Regional Clinical Hospital, Tula, Russia, ¹⁶Tula State Medical University, Tula, Russia, ¹⁷Petrozavodsk State University, Petrozavodsk, Russia, ¹⁸Regional Clinical Hospital, Samara, Russia, ¹⁹Regional Clinical Hospital, Ulyanovsk, Russia, ²⁰Smolensk State Medical University, Smolensk, Russia, ²¹National Medical and Surgical Center named after N.I. Pirogov” of the Ministry of Healthcare of the Russian Federation, Moscow, Russia, ²²Regional Clinical Hospital, Krasnodar, Russia, ²³Moscow Clinical Scientific and Practical Centre named after Loginov A.S., Moscow, Russia, ²⁴Medical Clinical Centre, Smolensk, Russia
Background/Purpose: to investigate the correlation between the rapid analgesic effect of tofacitinib and a decrease in RA activity after 3 and 6 months.Methods: The study…
Abstract Number: L14 • 2019 ACR/ARP Annual Meeting
Tofacitinib as Monotherapy Following Methotrexate Withdrawal in Patients with Psoriatic Arthritis Previously Treated with Open-label Tofacitinib + Methotrexate: A Randomized, Placebo-controlled Sub-study of OPAL Balance
Peter Nash¹, Laura Coates ², Philip J. Mease ³, Alan Kivitz ⁴, Dafna Gladman ⁵, Frank Behrens ⁶, James C Wei ⁷, Dona Fleishaker ⁸, Joseph Wu ⁸, Cunshan Wang ⁸, Ana Romero ⁹, Lara Fallon ¹⁰, Ming-Ann Hsu ⁸ and Keith Kanik ⁸, ¹Griffith University, Brisbane, Queensland, Australia, ²University of Oxford, Oxford, United Kingdom, ³Swedish Medical Center and University of Washington, Seattle, Washington, ⁴Altoona Center for Clinical Research, Duncansville, ⁵University of Toronto, Toronto, Canada, ⁶CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ⁷Chung Shan Medical University, Taichung City, Taiwan (Republic of China), ⁸Pfizer Inc, Groton, Connecticut, ⁹Pfizer Inc, Barcelona, Spain, ¹⁰Pfizer Inc, Montreal, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Tofacitinib monotherapy has not been previously studied in PsA. This sub-study of…
Abstract Number: L22 • 2019 ACR/ARP Annual Meeting
Tofacitinib for the Treatment of Polyarticular Course Juvenile Idiopathic Arthritis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Withdrawal Study
Hermine Brunner¹, Olga Synoverska ², Tracy Ting ³, Carlos Abud Mendoza ², Alberto Spindler ², Yulia Vyzhga ², Katherine Marzan ³, Vladimir Keltsev ², Irit Tirosh ², Lisa Imundo ³, Rita Jerath ³, Daniel Kingsbury ³, Betul Sozeri ², Sheetal Vora ³, Sampath Prahalad ³, Elena Zholobova ², Yonatan Butbul Aviel ², Vyacheslav Chasnyk ², Melissa Lerman ³, Kabita Nanda ³, Heinrike Schmeling ³, Heather Tory ³, Yosef Uziel ², Diego Oscar Viola ², Holly Posner ⁴, Keith Kanik ⁵, Ann Wouters ⁴, Cheng Chang ⁵, Richard Zhang ⁴, Irina Lazariciu ⁶, Ming-Ann Hsu ⁵, Ricardo Suehiro ⁷, Alberto Martini ², Daniel J. Lovell ³ and Nicolino Ruperto ⁸, ¹PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, ⁴Pfizer Inc, New York, New York, ⁵Pfizer Inc, Groton, Connecticut, ⁶IQVIA, Montreal, Quebec, Canada, ⁷Pfizer Inc, Collegeville, Pennsylvania, ⁸PRINTO, Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for JIA. Here we assess the efficacy and safety of tofacitinib in patients (pts)…
Abstract Number: 1413 • 2019 ACR/ARP Annual Meeting
Efficacy of Tofacitinib Monotherapy, Tofacitinib with Methotrexate and Adalimumab with Methotrexate in Patients with Early ( ≤ 2 Years) vs Established ( > 2 Years) Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Strategy
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Naonobu Sugiyama ³, Noriko Iikuni ⁴, Koshika Soma ⁵, Harry Shi ⁶, Eduardo Mysler ⁷, Robert J. Moots ⁸, Josef Smolen ⁹ and Roy Fleischmann ¹⁰, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Pfizer Japan Inc, Tokyo, Japan, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Organización Médica de Investigación, Buenos Aires, Argentina, ⁸Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, ⁹Medical University of Vienna, Vienna, Austria, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Greater improvements in efficacy outcomes have been reported with tofacitinib 5 mg BID ±…
Abstract Number: 1428 • 2019 ACR/ARP Annual Meeting
Time to Discontinuation of Tofacitinib in Rheumatoid Arthritis Patients with and Without Methotrexate: Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Angela Cesta ², Xiuying Li ², Edward Keystone ¹, Claire Bombardier ² and And Other OBRI Investigators ², ¹Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug which can be used as an alternative to biologic disease modifying antirheumatic drugs (bDMARDs) for rheumatoid…
Abstract Number: 1484 • 2019 ACR/ARP Annual Meeting
The Impact of Time Since First Diagnosis on the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis
Peter Nash¹, Maria Greenwald ², Liang-Hung Lin ³, Wei Yu ⁴, Paul Santos Estrella ⁵, Rajiv Mundayat ⁶, Daniela Graham ⁷ and Douglas Veale ⁸, ¹University of Queensland, Brisbane, Queensland, Australia, ²Desert Medical Advances, Palm Desert, CA, ³AIR, Taichung Tzu Chi Hospital, Taichung City, Taiwan (Republic of China), ⁴Pfizer Inc, Beijing, China (People's Republic), ⁵Pfizer Inc, Makati, Philippines, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland
Background/Purpose: Early identification, diagnosis, and treatment of psoriatic arthritis (PsA) is important in preventing long-term joint damage and disability, and the associated socioeconomic consequences.1 Tofacitinib…
Abstract Number: 1502 • 2019 ACR/ARP Annual Meeting
The Effect of Tofacitinib on Residual Pain in Patients with Psoriatic Arthritis
Maxime Dougados¹, Désirée van der Heijde ², Clifton Bingham ³, Peter Taylor ⁴, Lara Fallon ⁵, John Woolcott ⁶, Yves Brault ⁷, Lisy Wang ⁸ and Meriem Kessouri ⁷, ¹Cochin Hospital, Paris, France, ²Leiden University Medical Center, Leiden, Netherlands, ³Johns Hopkins University, Baltimore, MD, ⁴University of Oxford, Oxford, United Kingdom, ⁵Pfizer Inc, Montreal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Paris, France, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Current treatments for PsA have proven effective in reducing patient (pt)-reported pain;1,2 however, residual pain often remains. Tofacitinib is an oral Janus kinase inhibitor…
Abstract Number: 1513 • 2019 ACR/ARP Annual Meeting
Impact of Baseline Body Mass Index on the Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis
Christopher Ritchlin¹, Alexis Ogdie ², Jon Giles ³, Juan Gomez-Reino ⁴, Philip Helliwell ⁵, Lori Stockert ⁶, Pamela Young ⁶, Wael Joseph ⁶, Rajiv Mundayat ⁷, Daniela Graham ⁸, John Woolcott ⁶ and Ana Romero ⁹, ¹Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ²Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ³Division of Rheumatology, Columbia University, New York, NY, ⁴Hospital Clínico Universitario, Santiago de Compostela, Spain, ⁵University of Leeds, Leeds, United Kingdom, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY, ⁸Pfizer Inc, Groton, CT, ⁹Pfizer Inc, Barcelona, Spain
Background/Purpose: Obesity is highly prevalent in PsA (~45%),1 and has previously been associated with a reduced response to TNF inhibitors.2 Tofacitinib is an oral Janus…
Abstract Number: 2372 • 2019 ACR/ARP Annual Meeting
Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five‑Year Results from a US-based Rheumatoid Arthritis Registry
Joel Kremer¹, Clifton Bingham ², Laura Cappelli ², Jeffrey Greenberg ³, Jamie Geier ⁴, Ann Madsen ⁴, Connie Chen ⁴, Alina Onofrei ⁵, Christine Barr ⁵, Dimitrios Pappas ⁶, Heather Litman ⁵, Kimberly Dandreo ⁵, Andrea Shapiro ⁷, Carol Connell ⁸ and Arthur Kavanaugh ⁹, ¹Albany Medical College, Albany, NY, ²Johns Hopkins University, Baltimore, MD, ³Corrona, LLC; NYU School of Medicine, Waltham, MA, ⁴Pfizer Inc, New York, NY, ⁵Corrona, LLC, Waltham, MA, ⁶Columbia University, New York, NY, ⁷Pfizer Inc, Peapack, NJ, ⁸Pfizer Inc, Groton, CT, ⁹University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Real‑world data (RWD) complement clinical trial data in assessing long-term safety. We evaluated…
Abstract Number: 2874 • 2019 ACR/ARP Annual Meeting
Comparison of Malignancy and Mortality Rates Between Tofacitinib and Biologic DMARDs in Clinical Practice: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
Joel Kremer¹, Clifton Bingham ², Laura Cappelli ², Jeffrey Greenberg ³, Ann Madsen ⁴, Jamie Geier ⁴, Jose L. Rivas ⁵, Alina Onofrei ⁶, Christine Barr ⁶, Dimitrios Pappas ⁷, Heather Litman ⁶, Kimberly Dandreo ⁶, Andrea Shapiro ⁸, Carol Connell ⁹ and Arthur Kavanaugh ¹⁰, ¹Albany Medical College, Albany, NY, ²Johns Hopkins University, Baltimore, MD, ³Corrona, LLC; NYU School of Medicine, Waltham, MA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer SLU, Madrid, Spain, ⁶Corrona, LLC, Waltham, MA, ⁷Columbia University, New York, NY, ⁸Pfizer Inc, Peapack, NJ, ⁹Pfizer Inc, Groton, CT, ¹⁰University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Real-world evidence (RWE) is key to understanding post-approval long-term safety of medications. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA.…
Abstract Number: 2900 • 2019 ACR/ARP Annual Meeting
Interferon Signature Predicts Response to Tofacitinib in Haploinsufficiency of A20
Sarah Blackstone¹, Daniella Schwartz ¹, Natalia Sampaio Moura ¹, Deborah Stone ¹, Meryl Waldman ¹, Patrycja Hoffmann ¹, Anne Jones ¹, Tina Romeo ¹, Karyl Barron ¹, Joshua Milner ¹, Daniel Kastner ¹ and Amanda Ombrello ¹, ¹National Institutes of Health, Bethesda, MD
Background/Purpose: The protein A20, encoded by TNFAIP3, represses signaling upstream of the inflammatory transcription factor nuclear factor (NF)-kB by regulating ubiquitination. Heterozygous loss-of-function mutations in…
Abstract Number: 11 • 2019 ACR/ARP Annual Meeting
Biomarker Changes for Patients with Rheumatoid Arthritis Receiving Tofacitinib with Methotrexate or Glucocorticoids vs Tofacitinib Monotherapy
Julie Lee¹, Xing Chen ¹, Weidong Zhang ¹, David Martin ¹, Craig Hyde ¹, Tomohiro Hirose ², Shweta Shah ³ and Lori Fitz ¹, ¹Pfizer Inc, Cambridge, MA, ²Pfizer Japan Inc, Toyko, Japan, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Herpes zoster (HZ) is more common in patients (pts) with RA vs…
Abstract Number: 943 • 2019 ACR/ARP Annual Meeting
A Phase 1b/2a Trial of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus
Sarfaraz Hasni¹, Sarthak Gupta ², Michael Davis ³, Elaine Poncio ⁴, Yenealem Temesgen-Oyelakin ⁴, Phillip Carlucci ⁴, Xinghao Wang ⁴, Mohammad Naqi ⁴, Martin Playford ⁵, Rishi Goel ⁴, Xiaobai Li ⁶, Ann Biehl ⁴, Isabel Ochoa-Navas ⁴, Zerai Manna ⁴, Yinghui Shi ⁷, Don Thomas ⁸, Jinguo Chen ⁹, Angélique Biancotto ⁹, Richard Apps ⁹, Foo Cheung ⁹, Yuri Kotliarov ⁹, Ashley Babyak ⁶, Katie Stagliano ⁹, John Tsang ⁹, Wanxia Tsai ¹⁰, Laura Vian ¹⁰, Nathalia Gazaniga ⁴, Valentina Giudice ⁴, Stephen Brooks ¹¹, Meggan Mackay ¹², Peter Gregersen ¹³, Betty Diamond ¹⁴, Nehal Mehta ¹⁵, Alan Remaley ⁵, John O'Shea ¹⁶, Massimo Gadina ¹⁰ and Mariana Kaplan ¹⁶, ¹National Institute of Arthritis, Musculoskeletal, and Skin diseases/ National Institutes of Health, Bethesda, MD, ²Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, ³NIAMS/NIH, Bethesda, MD, ⁴NIAMS/NIH, Bethesda, ⁵NHLBI/NIH, Bethesda, ⁶Clinical Center/NIH, Bethesda, ⁷Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁸Walter Reed National Military Medical Center, Bethesda, MD, ⁹NIAID/NIH, Bethesda, ¹⁰Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ¹¹Biomining and Discovery Section/NIAMS/NIH, Bethesda, MD, ¹²Feinstein Institute for Medical Research, New York, ¹³Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁴Feinstein Institutes of Medical Research, Manhasset, NY, ¹⁵National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ¹⁶National Institute of Arthritis, Musculoskeletal, and Skin diseases/ National Institutes of Health, Bethesda
Background/Purpose: A pharmacologic intervention that modulates JAK/STAT signaling pathways represents a novel approach for the treatment of Systemic Lupus Erythematosus (SLE). In animal models of…
Abstract Number: 1377 • 2019 ACR/ARP Annual Meeting
MTX Withdrawal in Patients with RA Who Achieve Low Disease Activity with Tofacitinib Modified-Release 11 Mg Once Daily + MTX: An Assessment of the Impact on the Short Form-36 Patient-Reported Outcome
Vibeke Strand¹, Janet Pope ², John Woolcott ³, Jose L. Rivas ⁴, Annette Diehl ³, Shixue Liu ⁵, David Gruben ⁶ and Stanley Cohen ⁷, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Western University, London, ON, Canada, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer SLU, Madrid, Spain, ⁵Pfizer Inc, Shanghai, China (People's Republic), ⁶Pfizer Inc, Groton, CT, ⁷Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib +/- background MTX has been shown to be an effective treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].